NASDAQ:RUBY - Rubius Therapeutics Stock Price, Forecast & News

$8.61

+0.11 (+1.29 %)

(As of 01/22/2020 12:31 PM ET)

Add

Compare

Today's Range

$8.38

Now: $8.61▼

$8.61

50-Day Range

$8.27

MA: $10.59▼

$14.12

52-Week Range

$6.96

Now: $8.61▼

$20.04

Volume8,637 shs

Average Volume425,654 shs

Market Capitalization$687.08 million

P/E RatioN/A

Dividend YieldN/A

Beta2.27

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:RUBY

Previous Symbol

CUSIPN/A

CIKN/A

Webhttp://www.rubiustx.com/

Phone617-679-9600

Debt

Debt-to-Equity Ratio0.30

Current Ratio9.83

Quick Ratio9.83

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.97 per share

Price / Book1.73

Profitability

EPS (Most Recent Fiscal Year)($2.27)

Net Income$-89,190,000.00

Net MarginsN/A

Return on Equity-41.30%

Return on Assets-32.65%

Miscellaneous

Employees142

Outstanding Shares79,800,000

Market Cap$687.08 million

Next Earnings Date3/26/2020 (Estimated)

OptionableNot Optionable

Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter.

(Ad)

A U.S. congressional committee passed important legislation that enables each state to set its own policies around cannabis… This bill also allows states to expunge federal marijuana convictions and arrests. This will likely lead to federal legalization sooner than expected. Get in early and you just might be the next 'Marijuana Millionaire'...

Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics Inc (NASDAQ:RUBY) posted its earnings results on Thursday, November, 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.06. During the same quarter in the prior year, the firm posted ($0.42) earnings per share. View Rubius Therapeutics' Earnings History.

When is Rubius Therapeutics' next earnings date?

Rubius Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Rubius Therapeutics.

What price target have analysts set for RUBY?

4 brokerages have issued 12 month price objectives for Rubius Therapeutics' shares. Their forecasts range from $4.00 to $40.00. On average, they anticipate Rubius Therapeutics' stock price to reach $22.75 in the next twelve months. This suggests a possible upside of 164.2% from the stock's current price. View Analyst Price Targets for Rubius Therapeutics.

What is the consensus analysts' recommendation for Rubius Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rubius Therapeutics.

What are Wall Street analysts saying about Rubius Therapeutics stock?

Here are some recent quotes from research analysts about Rubius Therapeutics stock:

1. According to Zacks Investment Research, "Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States. " (11/20/2019)
2. HC Wainwright analysts commented, "We have currently only assigned value to RTX-134 in PKU and RTX-240 in NSCLC. Our price target of $40/share is based on an equally-weighted composite of: (a) $40.7/share, as a 30x multiple of taxed and diluted $21.95 discounted back to FY19 at 20% (in line with the expected P/E multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $39.4/share (discounted cash flow analysis using a 20% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (6/26/2019)

Has Rubius Therapeutics been receiving favorable news coverage?

News headlines about RUBY stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rubius Therapeutics earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Rubius Therapeutics.

Are investors shorting Rubius Therapeutics?

Rubius Therapeutics saw a increase in short interest in December. As of December 31st, there was short interest totalling 9,800,000 shares, an increase of 7.5% from the December 15th total of 9,120,000 shares. Based on an average daily volume of 399,100 shares, the days-to-cover ratio is currently 24.6 days. Currently, 33.1% of the shares of the company are short sold. View Rubius Therapeutics' Current Options Chain.

Who are some of Rubius Therapeutics' key competitors?

Some companies that are related to Rubius Therapeutics include Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Regenxbio (RGNX), Cortexyme (CRTX), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Alector (ALEC), Orchard Therapeutics (ORTX), Coherus Biosciences (CHRS), DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG), Aerie Pharmaceuticals (AERI), Sangamo Therapeutics (SGMO) and Mesoblast (MESO).

What other stocks do shareholders of Rubius Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Aclaris Therapeutics (ACRS), Dicerna Pharmaceuticals (DRNA), Momo (MOMO), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), ProQR Therapeutics (PRQR), Portola Pharmaceuticals (PTLA) and AT&T (T).

Who are Rubius Therapeutics' key executives?

Rubius Therapeutics' management team includes the folowing people:

Mr. David R. Epstein, Exec. Chairman (Age 57)
Dr. Christopher L. Carpenter M.D., Ph.D., Chief Medical Officer (Age 63)
Dr. Pablo J. Cagnoni, CEO, Pres & Director (Age 56)
Mr. Andrew M. Oh, Chief Financial Officer (Age 47)
Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 50)

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Alpine Global Management LLC (0.10%) and NEXT Financial Group Inc (0.01%). Company insiders that own Rubius Therapeutics stock include Christopher L Carpenter, Francis M Cuss, Robert Langer and Torben Straight Nissen. View Institutional Ownership Trends for Rubius Therapeutics.

Which institutional investors are buying Rubius Therapeutics stock?

RUBY stock was acquired by a variety of institutional investors in the last quarter, including Alpine Global Management LLC and NEXT Financial Group Inc. View Insider Buying and Selling for Rubius Therapeutics.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $8.61.

How big of a company is Rubius Therapeutics?

Rubius Therapeutics has a market capitalization of $687.08 million. The company earns $-89,190,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis. Rubius Therapeutics employs 142 workers across the globe.View Additional Information About Rubius Therapeutics.

What is Rubius Therapeutics' official website?

The official website for Rubius Therapeutics is http://www.rubiustx.com/.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]

MarketBeat Community Rating for Rubius Therapeutics (NASDAQ RUBY)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		146 (Vote Outperform)
Underperform Votes:		168 (Vote Underperform)
Total Votes:		314

MarketBeat's community ratings are surveys of what our community members think about Rubius Therapeutics and other stocks. Vote "Outperform" if you believe RUBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RUBY will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/22/2020 by MarketBeat.com Staff

Your Ultimate Investing Toolkit

Just $1.00 for your first month.